BIO-TECHNE Corp (TECH) FY2026 Annual Statement of Cash Flows

Statement of Cash Flows

2025-07-01 to 2026-06-30

Swipe to see the full flow
BIO-TECHNE Corp cash flow reconciliation, Jul 1, 2025 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net earnings → Net cash from operating activities: $181,862,000.00Depreciation and amortization → Operating adjustments reconciliation: $97,359,000.00Stock-based compensation expense → Operating adjustments reconciliation: $41,365,000.00Deferred income taxes → Operating adjustments reconciliation: $13,196,000.00Loss on investments → Operating adjustments reconciliation: $5,862,000.00Prepaid expenses → Operating adjustments reconciliation: $5,264,000.00Asset impairment restructuring → Operating adjustments reconciliation: $3,914,000.00Trade accounts payable, accrued expenses, contract liabilities, and other → Operating adjustments reconciliation: $3,180,000.00Other operating activity → Operating adjustments reconciliation: $477,000.00Operating adjustments reconciliation → Net cash from operating activities: $110,211,000.00Operating adjustments reconciliation → Income taxes payable: $23,051,000.00Operating adjustments reconciliation → Trade accounts and other receivables, net: $10,793,000.00Operating adjustments reconciliation → Inventories: $8,232,000.00Operating adjustments reconciliation → Salaries, wages and related accruals: $7,671,000.00Operating adjustments reconciliation → (Recovery) Impairment of assets held-for-sale: $6,789,000.00Operating adjustments reconciliation → Leases, net: $2,983,000.00Operating adjustments reconciliation → (Gain) Loss on equity method investment: $887,000.00Distributions from Wilson Wolf → investing reconciliation: $6,043,000.00Proceeds from sale of assets held-for-sale → investing reconciliation: $4,617,000.00investing reconciliation → Additions to property and equipment: $28,850,000.00Net cash used in financing activities → financing reconciliation: $169,114,000.00Proceeds from stock option exercises → financing reconciliation: $80,618,000.00financing reconciliation → Repayments of long-term debt: $146,000,000.00financing reconciliation → Cash dividends: $49,916,000.00financing reconciliation → Repurchases of common stock: $41,675,000.00financing reconciliation → Taxes paid on RSUs and net share settlements: $12,141,000.00Net cash used in investing activities → investing reconciliation: $18,190,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $162,186,000.00Net cash from operating activities → Cash sources and uses: $292,073,000.00Cash sources and uses → Exchange-rate effect: $2,243,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $264,712,000.00Cash sources and uses → Net cash used in investing activities: $18,190,000.00Cash sources and uses → Net cash used in financing activities: $169,114,000.00Net earnings: $181,862,000.00Net earnings+$181.86 MDepreciation and amortization: $97,359,000.00Depreciation & amortization+$97.36 MDeferred income taxes: $13,196,000.00Deferred taxes & credits+$13.20 MStock-based compensation expense: $41,365,000.00Stock-based compensation+$41.37 M(Gain) Loss on equity method investment: -$887,000.00Equity-method sale gain & loss−$887.00 KLoss on investments: $5,862,000.00Investment value change+$5.86 MAsset impairment restructuring: $3,914,000.00Asset impairment restructuring+$3.91 M(Recovery) Impairment of assets held-for-sale: -$6,789,000.00Held-for-sale asset impairment−$6.79 MLeases, net: -$2,983,000.00Leases, net−$2.98 MOther operating activity: $477,000.00Other operating, net+$477.00 KTrade accounts and other receivables, net: -$10,793,000.00Accounts & other receivables−$10.79 MInventories: -$8,232,000.00Inventories−$8.23 MPrepaid expenses: $5,264,000.00Prepaid expenses+$5.26 MTrade accounts payable, accrued expenses, contract liabilities, and other: $3,180,000.00Payables & accrued liabilities+$3.18 MSalaries, wages and related accruals: -$7,671,000.00Accrued compensation−$7.67 MIncome taxes payable: -$23,051,000.00Income taxes payable−$23.05 MNet cash from operating activities: $292,073,000.00Operating cash+$292.07 MOperating adjustments reconciliation: $170,617,000.00Cash dividends: -$49,916,000.00Common dividends paid−$49.92 MProceeds from stock option exercises: $80,618,000.00Stock option exercises+$80.62 MRepurchases of common stock: -$41,675,000.00Common stock repurchases−$41.68 MRepayments of long-term debt: -$146,000,000.00Credit line repayments−$146.00 MTaxes paid on RSUs and net share settlements: -$12,141,000.00Stock-award tax withholding−$12.14 MNet cash used in financing activities: -$169,114,000.00. Cash required to fund net payments.Financing cash−$169.11 Mfinancing reconciliation: $249,732,000.00Additions to property and equipment: -$28,850,000.00PP&E purchases−$28.85 MDistributions from Wilson Wolf: $6,043,000.00Equity-method return of capital+$6.04 MProceeds from sale of assets held-for-sale: $4,617,000.00Held-for-sale asset sales+$4.62 MNet cash used in investing activities: -$18,190,000.00. Cash required to fund net payments.Investing cash−$18.19 Minvesting reconciliation: $28,850,000.00Cash sources and uses: $454,259,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $162,186,000.00Beginning cash$162.19 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $264,712,000.00Ending cash$264.71 MExchange-rate effect: -$2,243,000.00FX effect−$2.24 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$263.22 MOperating cash − cash spent on PP&ECash flow / Net income1.61×Operating cash flow ÷ net incomeNet cash change+$102.53 MEnding cash − beginning cash
Chart details

BIO-TECHNE Corp cash flow reconciliation, Jul 1, 2025 through Jun 30, 2026

Cash flows for Jul 1, 2025 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Jun 30, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Jun 30, 2025
162,186,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
292,073,000 US dollars. Net cash provided.
Net earnings
181,862,000 US dollars
Depreciation and amortization
97,359,000 US dollars
Deferred income taxes
13,196,000 US dollars
Stock-based compensation expense
41,365,000 US dollars
(Gain) Loss on equity method investment
negative 887,000 US dollars
Loss on investments
5,862,000 US dollars
Asset impairment restructuring
3,914,000 US dollars
(Recovery) Impairment of assets held-for-sale
negative 6,789,000 US dollars
Leases, net
negative 2,983,000 US dollars
Other operating activity
477,000 US dollars
Trade accounts and other receivables, net
negative 10,793,000 US dollars
Inventories
negative 8,232,000 US dollars
Prepaid expenses
5,264,000 US dollars
Trade accounts payable, accrued expenses, contract liabilities, and other
3,180,000 US dollars
Salaries, wages and related accruals
negative 7,671,000 US dollars
Income taxes payable
negative 23,051,000 US dollars
Investing activities
negative 18,190,000 US dollars. Net cash used.
Additions to property and equipment
negative 28,850,000 US dollars
Distributions from Wilson Wolf
6,043,000 US dollars
Proceeds from sale of assets held-for-sale
4,617,000 US dollars
Financing activities
negative 169,114,000 US dollars. Net cash used.
Cash dividends
negative 49,916,000 US dollars
Proceeds from stock option exercises
80,618,000 US dollars
Repurchases of common stock
negative 41,675,000 US dollars
Repayments of long-term debt
negative 146,000,000 US dollars
Taxes paid on RSUs and net share settlements
negative 12,141,000 US dollars
Operating adjustment reconciliation
170,617,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
249,732,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
28,850,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 2,243,000 US dollars
Ending cash on Jun 30, 2026
264,712,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
454,259,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
102,526,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.61×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
292,073,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
28,850,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
263,223,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $110.21M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 292,073,000 US dollars minus 28,850,000 US dollars equals 263,223,000 US dollars.
BIO-TECHNE Corp (TECH) FY2026 Annual Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!